A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

Completed · Phase 1

Conditions studied: Healthy Subjects

In brief

This is a study to determine the safety and pharmacokinetics of CDX-0159 administered subcutaneously in healthy subjects.

Key facts

Study ID
NCT05031624
Run by
Celldex Therapeutics
People needed
32
Starts
2021-08-30
Expected to finish
2022-01-14
Last updated by the study team
2022-01-21

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.